Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7Polycystic Ovary Syndrome 3Peripheral Nervous System Diseases 2Neoplasms 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Overweight 1Osteosarcoma 1Obesity 1Neuroblastoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Motor Activity 1Mesothelioma 1Meningioma 1Medulloblastoma 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 IHC3+ Advanced Colorectal Cancer × Tablets × 1 year × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡